Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AgfiledCriticalSchering Ag
Priority to UY26539ApriorityCriticalpatent/UY26539A1/en
Publication of UY26539A1publicationCriticalpatent/UY26539A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Una composición farmacéutica que comprende como un primer ingrediente activo un estrógeno, tal como estradiol o valerato de estradiol, en cantidades suficientes para tratar desórdenes y síntomas asociados con niveles endógenos deficientes de estrógeno en mujeres, y como un segundo ingrediente activo 6b, 7b; 15b; 16b-dimentil-3-oxo-17a-preg-4-eno-21, 17-carbolactona (drospirenona, DRSP) en cantidades suficientes para proteger el endometrio de los efectos adversos del estrógeno.A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in amounts sufficient to treat disorders and symptoms associated with endogenous estrogen deficient levels in women, and as a second active ingredient 6b, 7b; 15b; 16b-dimethyl-3-oxo-17a-preg-4-ene-21, 17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen.
UY26539A2001-01-152001-01-15
DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY.
UY26539A1
(en)
15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases.
17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS.
CONTRACEPTIVE REGIME OF THE "PROGESTAGEN ONLY" TYPE WHICH ALLOWS A GOOD CONTROL OF THE CYCLE AND CONTRACEPTIVE EFFECTIVENESS, WHERE THE PROGESTAGEN IS SUPPLIED IN TWO PHASES
COMPOSITIONS FOR INJECTION ONCE A MONTH, WHICH CONSTITUTES A CONTRACEPTIVE MEDICATION OF PROLONGED ACTION, SUITABLE FOR THERAPY OF REPLACEMENT OF HORMONES IN PERIMENOPAUSIC AND PREMONOPAUSIC WOMEN.